New Dopamine Agonist for Parkinson's, Artificial Intelligence in Medical Journals, Coffee and Dementia Risk
Neurology Today in 5Show Notes
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about a new selective dopamine agonist for people with Parkinson's disease, the use of artificial intelligence in preparing journal manuscripts, and caffeinated coffee's role in reducing dementia risk.
More from Neurology Today in 5
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the use of lamotrigine during pregnancy, the value of professional mentorship, and the misdiagnosis of CADASIL as multiple sclerosis.
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the pros and cons of wearable devices, new data for thrombectomy use in medium-vessel occlusion strokes, and a new treatment for limb-girdle muscular dystrophy type 2I/R9.
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the first oral PCSK9 inhibitor, the transforming role of the neurology department chair, and anti-IgLON5 disease.
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about new migraine prevention guidelines, the use of plasmapheresis for acute MOGAD attacks, and how sabbaticals can help neurologists avoid burnout.
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about the impact of the "One Big Beautiful Bill Act" on neurology practice and research, how artificial intelligence is transforming the neurologist's workload, and the relationship between GBA1 mutations and Parkinson's disease.